Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells $223,947.99 in Stock

23 Jan 2026, 17:00 by Scott Moore · The Cerbat Gem

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CFO Timothy Eugene Sullivan sold 10,287 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $223,947.99. Following the sale, the chief financial officer directly owned 93,901 shares of the company’s stock, valued at $2,044,224.77. The trade was a 9.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

On Tuesday, January 20th, Timothy Eugene Sullivan sold 2,892 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $19.79, for a total transaction of $57,232.68.
On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total transaction of $85,564.64.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock traded down $0.25 on Friday, hitting $21.76. The stock had a trading volume of 2,214,978 shares, compared to its average volume of 3,258,745. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $30.91. The business’s 50 day moving average is $22.99 and its two-hundred day moving average is $23.49. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.64. The business had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The firm’s quarterly revenue was up 133.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.46) EPS. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Simplify Asset Management Inc. acquired a new stake in Apellis Pharmaceuticals in the third quarter valued at approximately $2,419,000. Corton Capital Inc. bought a new position in shares of Apellis Pharmaceuticals in the 2nd quarter valued at $364,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock valued at $1,838,000 after acquiring an additional 30,507 shares in the last quarter. Highland Capital Management LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter worth $1,135,000. Finally, Schroder Investment Management Group increased its holdings in Apellis Pharmaceuticals by 91.9% in the 2nd quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock worth $8,406,000 after purchasing an additional 232,506 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Analyst Upgrades and Downgrades

Several analysts have weighed in on APLS shares. Mizuho dropped their price objective on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. HC Wainwright dropped their price target on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Wolfe Research began coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 29th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $19.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Twelve investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.53.

View Our Latest Research Report on APLS

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.